Authors are requested to submit the manuscripts only through IJAM web portal, submission directly to journal mail ids will not be considered.
IJAM is now a member of Crossref. Articles published from the year 2017 onwards are assigned to DOI. • Articles are invited for the first issue of the year 2022.
President - Medical and Regulatory Affairs, Aristo Pharmaceuticals Private LimitedMumbai – 400053
Ind.J.Applied.Microbiol. 2021 .23(2) : 47-55
Antibiotic resistance has become the most importunate health issueand remains a major public health concern worldwide. Production of extended spectrumβ-lactamases (ESBL) is one of the major causes of resistance to β-lactam antibiotics. Severalin-vitro studies have demonstrated the significant impact of inoculum size on the effectiveness ofβ-lactam-β-lactamase inhibitor combination. Higher concentration of β-lactamase inhibitor(Sulbactam) will be needed to combat the increased production of ESBLs in infections with highinoculum. The primary objective of the present study is to evaluate Minimum InhibitoryConcentration (MICs) of ESBL producing Enterobacteriaceae, against Ceftriaxone alone andCeftriaxone with Sulbactam combination (1:1 and 2:1) in presence of normal and higher inoculumof these bacteria. The secondary objective of the study is to demonstrate the in-vitro efficacy ofCeftriaxone-Sulbactam (CS) in presence of higher inoculum of bacteria.
Keywords: Ceftriaxone-Sulbactam combination, Extended-spectrum β-lactamases (ESBL),Inoculum effect, Antibiotic resistance, Escherichia coli, Klebsiella pneumonia
Download this article as